Tasadenoturev · DNX-2401

What is Tasadenoturev?

Tasadenoturev (DNX-2401) is an oncolytic adenovirus serotype 5 selectively replication-competent in tumor cells defective in the Rb/p16 pathway. It contains an RGD-4C integrin-binding motif enabling CAR-independent infection. The virus replicates in and lyses tumor cells, and is studied in diffuse intrinsic pontine glioma and diffuse midline glioma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

DNX-2401

Drug type

Oncolytic virus (Adenoviral vector)

Targets

retinoblastoma gene (Rb) (RB1) (biomarker), cyclin-dependent kinase inhibitor-2A (p16) (CDKN2A) (biomarker)

Mechanism

Kills target cells, directed at retinoblastoma gene (Rb) (RB1)

Pathways

cell cycle, G1 restriction point

Therapy area

Oncology

Developer

DNAtrix, Inc.

In trials of

JAZZ

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 2

UNII

79ME7DT193

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-MutantRecurrent Diffuse Intrinsic Pontine GliomaRecurrent Diffuse Midline Glioma, H3 K27M-MutantRecurrent WHO Grade III GliomaWHO Grade III Glioma

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT05009992

Updated Oct 3, 2026.